NeuroSense Therapeutics Files 6-K Report

Ticker: NRSN · Form: 6-K · Filed: 2026-04-06T09:20:35-04:00

Sentiment: neutral

Topics: foreign-issuer, regulatory-filing, press-release

TL;DR

NeuroSense Therapeutics filed a 6-K on 4/6/26 with a press release. Check for updates.

AI Summary

NeuroSense Therapeutics Ltd. filed a Form 6-K on April 6, 2026, reporting as a foreign private issuer. The filing includes a press release dated April 6, 2026, and related graphic materials. The company's mailing and business address is in Herzliya, Israel.

Why It Matters

This filing provides an update on NeuroSense Therapeutics' regulatory status and includes a press release, which may contain important business or financial information for investors.

Risk Assessment

Risk Level: low — A 6-K filing is a routine report for foreign issuers and does not inherently indicate significant risk.

Key Players & Entities

FAQ

What is the primary purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers which provides information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What documents are included in this specific 6-K filing?

This filing includes a 'REPORT OF FOREIGN PRIVATE ISSUER' (ea0285169-6k_neuro.htm), a 'PRESS RELEASE DATED APRIL 6, 2026' (ea028516901ex99-1.htm), and associated graphic materials.

Where is NeuroSense Therapeutics Ltd. based?

NeuroSense Therapeutics Ltd. has its mailing and business address at 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562, indicating it is based in Israel.

What is the CIK number for NeuroSense Therapeutics Ltd.?

The CIK number for NeuroSense Therapeutics Ltd. is 0001875091.

What is the SIC code listed for NeuroSense Therapeutics Ltd.?

The SIC code listed is 2834 for Pharmaceutical Preparations, within the Life Sciences sector.

From the Filing

EDGAR Filing Documents for 0001213900-26-040185 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001213900-26-040185 Filing Date 2026-04-06 Accepted 2026-04-06 09:20:35 Documents 3 Period of Report 2026-04-06 Document Format Files Seq Description Document Type Size 1 REPORT OF FOREIGN PRIVATE ISSUER ea0285169-6k_neuro.htm 6-K 11666 2 PRESS RELEASE DATED APRIL 6, 2026 ea028516901ex99-1.htm EX-99.1 15722 3 GRAPHIC ea028516901_ex99-1img1.jpg GRAPHIC 31293 Complete submission text file 0001213900-26-040185.txt 71718 Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142 NeuroSense Therapeutics Ltd. (Filer) CIK : 0001875091 (see all company filings) EIN. : 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231 Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 26839734 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)

View on Read The Filing